Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE DEXILANT (DEXLANSOPRAZOLE) ANTITRUST LITIGATION
Case Number:
3:25-cv-02785
See also:
Court:
Nature of Suit:
Judge:
Firms
- Cotchett Pitre
- Covington & Burling
- DiCello Levitt
- Dillingham & Murphy
- Dugan Law Firm
- Girard Sharp
- Glancy Prongay
- Hagens Berman
- Hangley Aronchick
- Hausfeld LLP
- Hilliard Shadowen
- Husch Blackwell
- Kessler Topaz
- Roberts Law Firm US
- Safirstein Law
- Shub Johns
- Spector Roseman
- Sperling Kenny
Companies
- Albertsons Cos. Inc.
- CVS Health Corp.
- International Union Of Operating Engineers
- Supervalu Inc.
- Takeda Pharmaceutical Co. Ltd.
- The Kroger Co.
- United Food & Commercial Workers International Union
- Upsher-Smith Laboratories Inc.
Sectors & Industries:
-
February 06, 2026
Takeda Can't Ax Most Of Heartburn Drug Pay-For-Delay Suit
Takeda Pharmaceutical Co. and TWi Pharmaceuticals must face most of a proposed antitrust class action accusing them of delaying the release of the generic version of Takeda's heartburn medication Dexilant, causing Walgreens, Kroger and other retailers to pay more for the brand-name drug, a California federal judge ruled Friday.
-
March 26, 2025
Walgreens, Kroger Claim Takeda Cut Illegal TWi Generics Deal
Walgreens, Kroger, Albertsons and H-E-B hit Takeda and TWi Pharmaceuticals with an antitrust suit in California federal court Tuesday, accusing the pharmaceutical companies of conspiring to delay the release of the generic version of Takeda's heartburn medication Dexilant, causing the retailers to pay more for the brand-name drug.